roberta di fonte
Bari John Paul II Cancer Institute, National Cancer Institute Foundation (IRCCS)
Bari, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Bari John Paul II Cancer Institute, National Cancer Institute Foundation (IRCCS)
Bari, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Medical School, University of Cyprus
Nicosia, Cyprus
Review Editor
Cancer Molecular Targets and Therapeutics
University of Sussex
Brighton, United Kingdom
Review Editor
Cancer Molecular Targets and Therapeutics
Allina Health
Minneapolis, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Mayo Clinic
Rochester, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Tangdou Hospital, Fourth Military Medical University
Xian, China
Review Editor
Cancer Molecular Targets and Therapeutics
Yaroslav-the-Wise Novgorod State University
Veliky Novgorod, Russia
Review Editor
Cancer Molecular Targets and Therapeutics
National University of Singapore
Singapore, Singapore
Review Editor
Cancer Molecular Targets and Therapeutics
Faculty of Medicine, Mansoura University
Mansoura, Egypt
Review Editor
Cancer Molecular Targets and Therapeutics
Hebrew University of Jerusalem
Jerusalem, Israel
Review Editor
Cancer Molecular Targets and Therapeutics
University of Texas Medical Branch at Galveston
Galveston, United States
Review Editor
Cancer Molecular Targets and Therapeutics
University of Florida
Gainesville, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Divisione di oncologia medica, Ospedale Santa Maria delle Grazie
Pozzuoli, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Hebei Normal University
Shijiazhuang, China
Review Editor
Cancer Molecular Targets and Therapeutics
Roswell Park Comprehensive Cancer Center, University at Buffalo
Buffalo, United States
Review Editor
Cancer Molecular Targets and Therapeutics
University of Massachusetts Medical School
Worcester, United States
Review Editor
Cancer Molecular Targets and Therapeutics